Excellent or Good Hemostasis Achieved in 82 Percent of Evaluable Patients –. –Thrombotic Event Rate of 9.7 Percent Across All Patients, No Thrombotic Events ...
Thursday, 7 February 2019
Portola Pharmaceuticals Announces Full Results from the ANNEXA-4 Study of the Factor Xa Inhibitor Reversal Agent Andexxa® in Patients with Life-Threatening Bleeding - GlobeNewswire
Portola Pharmaceuticals Announces Full Results from the ANNEXA-4 Study of the Factor Xa Inhibitor Reversal Agent Andexxa® in Patients with Life-Threatening Bleeding GlobeNewswire
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment